0

Retinal Degenerative Diseases

Mechanisms and Experimental Therapy, Advances in Experimental Medicine and Biology 1074

Erschienen am 14.02.2019, 1. Auflage 2018
320,99 €
(inkl. MwSt.)

Lieferbar innerhalb 1 - 2 Wochen

In den Warenkorb
Bibliografische Daten
ISBN/EAN: 9783030092214
Sprache: Englisch
Umfang: xlii, 669 S., 49 s/w Illustr., 93 farbige Illustr.
Einband: kartoniertes Buch

Beschreibung

The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2014. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2018 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume.

Produktsicherheitsverordnung

Hersteller:
Springer Verlag GmbH
juergen.hartmann@springer.com
Tiergartenstr. 17
DE 69121 Heidelberg

Autorenportrait

John D. Ash, Ph.D., Francis M. Bullard Eminent Scholar Chair in Ophthalmological Sciences, Department of Ophthalmology, College of Medicine at the University of Florida. Dr. Ash received his Ph.D. from the Ohio State University Biochemistry Program in 1994, and completed postdoctoral training in the Cell Biology Department at Baylor College of Medicine, in Houston, Texas, and began his faculty career at the University of Oklahoma Health Sciences Center, Oklahoma. Dr. Ash is also a Visiting Professor at the Dalian Medical University, Dalian China. Dr. Ash has written and published 60 manuscripts including research articles, book chapters and invited reviews, and has edited four books.  He is currently an Executive editor for Experimental Eye research and a Scientific Review Editor for Molecular Vision. Dr. Ash is an active reviewer for these journals as well as Investigative Ophthalmology & Visual Science. In 2009, Dr. Ash received a research award from Hope for Vision, and in 2010 he received a Lew R. Wasserman Merit award from Research to Prevent Blindness, Inc. Dr. Ash has received grants from the National Institutes of Health, the Foundation Fighting Blindness, Research to Prevent Blindness, Inc., Hope for Vision, and the American Diabetes Association. Dr. Ash has served on the Program and Advocacy committees of the Association for Research in Vision and Ophthalmology. Dr. Ash has served on the scientific review panel for Fight For Sight (2005-2008) and is currently serving on the Scientific Advisory Board of the Foundation Fighting Blindness (Columbia, MD) where he chairs the review committee on Novel Medical Therapies Program. He also serves on the scientific review panel for the Macular Degeneration program of the BrightFocus Foundation (formerly the American Health Assistance Foundation, Clarksburg, MD).Robert Eugene Anderson, MD, Ph.D., is George Lynn Cross Research Professor, Dean A. McGee Professor of Ophthalmology, Professor of Cell Biology, and Adjunct Professor of Geriatric Medicine at The University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma. He is also Director of Research at the Dean A. McGee Eye Institute. He received his Ph.D. in Biochemistry (1968) from Texas A&M University and his MD from Baylor College of Medicine in 1975. In 1968, he was a postdoctoral fellow at Oak Ridge Associated Universities. At Baylor, he was appointed Assistant Professor in 1969, Associate Professor in 1976, and Professor in 1981. He joined the faculty of the University of Oklahoma Health Sciences Center in January of 1995. Dr. Anderson served as director of the Oklahoma Center for Neuroscience (1995-1999) and chairman of the Department of Cell Biology (1998-2007). He has received several honorary appointments including Visiting Professor, West China School of Medicine, Sichuan University, Chengdu, China; Honorary Professorship, Xi'an Jiaotong University, Xi'an, China; and Honorary Professor of Sichuan Medical Science Academy, Sichuan Provincial People's Hospital, Sichuan, China. Dr. Anderson has received the Sam and Bertha Brochstein Award for Outstanding Achievement in Retina Research from the Retina Research Foundation (1980), and the Dolly Green Award (1982) and two Senior Scientific Investigator Awards (1990 and 1997) from Research to Prevent Blindness, Inc. He received an Award for Outstanding Contributions to Vision Research from the Alcon Research Institute (1985), and the Marjorie Margolin Prize (1994). He has served on the editorial boards of Investigative Ophthalmology and Visual Science, Journal of Neuroscience Research, Neurochemistry International, Current Eye Research, and Experimental Eye Research. Dr. Anderson has published extensively in the areas of lipid metabolism in the retina and biochemistry of retinal degenerations. He has edited 18 books, 17 on retinal degenerations and one on the biochemistry of the eye. Dr. Anderson has received